(Oslo, Norway, 2 January 2015) Ms. Synne H. Røine resigns as CFO in Bionor Pharma ASA to accept an executive position in a private equity held Norwegian based company from 1. April 2015. The search for a replacement will start immediately.
"Synne H. Røine has contributed significantly to the strategic development of Bionor and we highly appreciate her dedication and service to Bionor Pharma over the last years and wish her all the best in her new position" said CEO Dr. Anker Lundemose.
Bionor Pharma ASA
CEO Dr. Anker Lundemose + 45 28 51 92 00
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
About Bionor Pharma ASA
Bionor Pharma is a leading biotechnology company, searching for breakthrough products for the treatment and prevention of life-threatening viral diseases. The Company is listed on the Oslo Stock Exchange, and is developing vaccines for viral infections. The vaccines are based on a proprietary technology platform developed following more than two decades of research into peptides, and they are designed to safely stimulate the immune system to combat viral diseases.
More information about Bionor Pharma is available at www.bionorpharma.com.